Vnitr Lek 2023, 69(2):89-104 | DOI: 10.36290/vnl.2023.016

News in diagnostics and treament of cardiomyopathies

Hana Poloczková¹, Tomáš Honek¹, Anna Chaloupka¹, Lukáš Opatřil^{1, 2}, Mária Bakošová¹, Jan Krejčí¹

¹ I. interní kardioangiologická klinika Fakultní nemocnice u sv. Anny v Brně a Lékařské fakulty Masarykovy univerzity

² Mezinárodní centrum klinického výzkumu Fakultní nemocnice u sv. Anny v Brně

Cardiomyopathies are defined as myocardial disorders in which the heart muscle is structurally and functionaly abnormal in the absence of a disease sufficient to cause this abnormality such as coronary artery disease, hypertension, valvular or congenital heart disease. According to the phenotype expresion cardiomyopathies are divided into dilated, hypertrophic, restrictive, arrhytmogenic and unclassified cardiomyopathies (noncompaction and tako-tsubo cardiomyopathy). The same phenotypic expression may include etiologically different forms of the disease, and at the same time phenotypic expression may change in many cardiomyopathies in the course of illness. For each type of cardiomyopathy, we further distinguish the familial (genetic) form and the acquired form. The clinical manifestation of the disease includes symptoms of heart failure, with reduced, mildly reduced or preserved ejection fraction, symptoms resulting from a number of arrhythmias and extracardiac symptoms, but in some cases symptoms may not be presented for a relatively long time. The disease can lead to significant morbidity and mortality if not detected and treated early, especially in young people who are frequently affected. Significant developments in diagnostic and treatment methods have led to an improvement in the prognosis of patients with cardiomyopathies in recent years.

Keywords: cardiac magnetic resonance, cardiomyopathy, genetic testing, heart failure.

Accepted: March 23, 2023; Published: March 30, 2023  Show citation